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the percentage of CCTA patients by 19.1%, shorter the diagnosis time by 8.45 
hours, decrease the length of stay by 0.64 days, increasing direct discharge rate 
by 9% and lower median cost of care per patient by 600 yuan while comparing 
to regular CT. ConClusions: Results of this study indicate more serviceable 
patient population, faster hospital discharge, shorter diagnosis time, length of 
stay and lower hospitalization costs with the use of revolution CT. The revolution 
CT is more cost effective.
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objeCtives: Approximately 18-20% of non-valvular atrial fibrillation (NVAF) 
patients are unable or unwilling to tolerate oral anticoagulant therapy (OAT), leav-
ing them at risk of stroke. Left atrial appendage closure (LAAC) device offers an 
alternative stroke risk reduction strategy that enables the majority of patients to dis-
continue long-term systematic OAT. Acknowledging both potential improvements 
in health outcomes and additional upfront implantation costs of a LAAC device, 
this study considers the lifetime costs and benefits of LAAC compared to aspirin 
plus clopidogrel (A+C) in high-risk NVAF patients ineligible or unwilling to take 
OAT from the Italian and Spanish public healthcare payer perspectives. Methods: 
A Markov model was constructed to assess the cost-effectiveness of LAAC com-
pared to A+C. Due to the lack of direct clinical trial data an indirect comparison 
was undertaken; having warfarin as the common comparator, PROTECT-AF (mean 
follow-up: 3.8 years) and ACTIVE-W (1.3 years) trials were used to indirectly com-
pare LAAC against A+C. Clinical results were combined with cost and utility data 
to assess the relative cost-effectiveness of the device. Furthermore, to reflect the 
real-world patient population, patients were stratified according to the severity of 
stroke and bleeding using CHA2DS2-VASc and HAS-BLED scores. Results: The 
base-case results demonstrate the LAAC as the cost-effective strategy compared 
to A+C in both countries with ICERs of € 5,116 per life-year gained (LYG) and € 3,942 
per quality-adjusted life year (QALY) gained for Italy, and € 10,298 per LYG and € 7,683 
per QALY gained for Spain. The ICERs per QALY gained are significantly below the 
willingness-to-pay thresholds generally accepted by each country: € 25,000 in Italy 
and € 30,000 in Spain. Results also demonstrate that the clinical benefit of LAAC 
becomes greater when risk of stroke and bleeding increases. ConClusions: LAAC 
device should be prioritised in patients who require an alternative to OAT and at 
relatively higher risk of stroke or bleeding.
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objeCtives: This study was carried out to assess, from the viewpoint of cost-effec-
tiveness, the optimum number of blood cultures for adults patients with infection 
in China. Methods: A decision tree was conducted for a cohort of Chinese adults 
aged 18 and above with infection and simulated the effects of only one-time, two-
time and three-time blood cultures. The detection rate and survival rate of compli-
cations were main outcomes and infectious endocarditis, meningitis, septic shock 
and kidney failure were considered as complications of infection in the model. The 
cost of blood culture, antibiotics and complications, the detection rate, incidence 
and survival rate of complications were collected from literature reviews. Sensitivity 
analyses were conducted to evaluate assumptions of the model and to identify 
which model inputs had most impact on the results. Results: The detection rate 
and the survival rate of complications were calculated as 65 and 97.9% for one-time 
blood culture, 80 and 98.0% for two-time blood cultures and 96 and 98.2% for three 
blood cultures, respectively. When using detection rate as outcome and willing to 
pay is more than RMB500 yuan, two-time blood cultures were cost-effective. The cost 
of blood culture and the detection rate will affect the results. When using survival 
rate of complications as outcome, two-time blood cultures was cost-saving and 
better than one-time blood culture. ConClusions: This analysis suggests that 
a 2-time blood culture collection method is recommended for blood culture for 
patients aged 18 and over with infection from the aspects of cost-effectiveness and 
diagnostic accuracy in China.
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objeCtives: The development of antidrug antibody (ADAb) causes the failure of ini-
tial tumor necrosis factor-alpha blocker (TNF-α blocker) in rheumatoid arthritis (RA) 
patients. Patients who develop ADAb against 1st TNF-blocker have a high likelihood 
of failing to 2nd TNF-blocker. ADAb-screening is commonly used as a supportive tool 
for switching to 2ndTNF-α blocker or non-TNF biologics in Europe but not standard 
of care in the United States. Moreover, no evidence of value of ADAb-screening 
in RA patients exists. This study estimated incremental effectiveness and cost of 
€ 1,639 and € 2,116, respectively, in prostate cancer. EPICUP was dominant versus 
ResponseDX in all adenocarcinomas. Regarding the comparison with diagnostic 
standard of care, the ICER was € 15,972 for breast cancer; € 25,932 for colon can-
cer; € 36,125 per QALY for pancreatic cancer; € 41,571 per QALY for NSCLC cancer; 
€ 28,881 per QALY for hepatocellular cancer; and € 6,771 per QALY for prostate cancer. 
These results were robust across deterministic and probabilistic sensitivity analy-
ses. ConClusions: From the Spanish NHS perspective, EPICUP is a cost-effective or 
dominant approach in comparison with other alternatives, including standardizing 
diagnostic methods (in this case when considering WTP threshold € 50,000), in all 
carcinoma analyzed, while improving patient care.
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objeCtives: To evaluate the cost-effectiveness of a new covered stent (WILLIS) 
vs. endovascular coil occlusion for the treatment of intracranial aneurysms in 
china. Methods: A decision tree model was constructed and the treatment 
impact was projected up to 6 months. 88 endovascular coil occlusion treated 
initial intracranial aneurysms patients and 34 recurrence intracranial aneurysms 
patient (with aneurysm diameter > 7 mm) charts were reviewed and direct medical 
cost data were collected from hospital information system in multi-hospitals in 
12 cities in China. Direct medical cost data, including drug cost, medical device 
cost, daily bed expenses, nursing fee, and examination cost were abstracted from 
the charts. The aneurysm recurrence rates by WILLIS and Coil treatments were 
obtained through literature review. The mortality rate of intracranial aneurysms 
recurrence, and side effects rates of treatments were collected through a direct 
expert survey. The main summary measure in this evaluation was incremental 
cost per death avoided. One way sensitivity analysis was performed to deter-
mine the robustness of the results. Results: The total direct medical cost was 
141,582.95 RMB and 177,407.35 RMB for Willis and coil occlusion treatments respec-
tively; the recurrence rate of intracranial aneurysms was 0% and28.9% for Willis 
and coil occlusion treatments in Chinese patients respectively; Relapse mortal-
ity of intracranial aneurysms is 0.2% in Chinese patients. The result suggests 
a dominant effect of Willis treatment over coil occlusion with an incremental 
cost-effectiveness ratio (ICER) of -63055263.7RMB/avoided death. This indicates 
that Willis treatment has demonstrated better efficacy and lower overall costs. 
The one-way sensitivity analysis didn’t change the conclusion, indicating the 
robustness of the results. ConClusions: Compared with endovascular coil 
occlusion, a new covered stent (WILLIS) improves clinical outcomes and reduces 
overall medical costs for the treatment of Chinese intracranial aneurysms patients 
(Diameter > 7 MM).
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objeCtives: The study –implemented after requirement of the National Cancer 
Institute (INC) - shows the results of a cost-effectiveness evaluation based on two 
alternative mechanisms: annual faecal immunochemical testing (FIT), and colonos-
copy every ten years in Argentina. Methods: The study develops a Markov model 
in ten stages, based on information provided by the INC, prior literature review and 
on-line questionnaires to physicians enrolled in the four major scientific societies 
related to cancer. Cost information arrived from the National Superintendence of 
Social Health Insurances and a sample of managers in social and private insur-
ance schemes. Results: The estimated model suggests that FIT annually applied 
becomes the most cost-effective screening method for CRC, in comparison with 
both no intervention and just colonoscopy. The incremental cost-effectiveness for 
annual FIT screening is USD 220.- per quality- adjusted life years (QUALY) against 
no-intervention, and the cost-effectiveness ratio is low and acceptable considering 
the WHO criteria (per capita GDP), in comparison to the cost-effectiveness ratios of 
other cardio-vascular preventive interventions prices in Argentina. ConClusions: 
Results of cost-effectiveness analyses are often strong associated to disbursements 
related to specific performance indicators, such as the challenges of implementing 
such initiatives under budget constraints and/or availability and quality of equip-
ments and human resources. These aspects were considered in the implementa-
tion of different scenarios in the sensitivity analysis, which includes adherence to 
treatments and capacity of accurate diagnoses, providing strength to the output 
reached in the research.
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objeCtives: This study aimed to estimate the proportion of patients increas-
ing while using revolution CT and to evaluate the impact of it in diagnosis time, 
length of stay, rate of direct discharge and hospitalization costs, while comparing 
to regular CT Methods: The data including rates, costs, time of diagnosis and 
length of stay, collected from literature reviewing and expert consultation, we use 
decision tree model to carry out a cost-effectiveness analysis by using treeage 
software Results: The study shows that with revolution CT, we can increase 
